They met in Hawaii and built a life in rural Maryland. This fall, they died two days apart.

When the chief barber retired, Doris took over the first chair. She knew everyone, said her grandson, Jeffrey Grim.

“When she was in the hospital, her respiratory therapist said, ‘Did you cut hair?’ and she was like, ‘Yeah,’ ” Grim recalled in an interview, describing Doris’s hospitalization for covid-19 this summer. The respiratory therapist then said, “ ‘My dad used to take me to you when I was a little boy.’ ”

Doris Bender died of complications of coronavirus on Sept. 3, in Room 4107 of Meritus Medical Center Intensive Care Unit in Robinwood. Jacob had died Sept. 1 in the same hospital, also of covid-19, in Room 4109.

Jacob, who was 83, died at 2:36 p.m.. Doris, who was 81, died at 2:34 p.m.

“Two days apart, two minutes apart, two rooms apart,” said Grim, a PhD candidate at the University of Michigan at Ann Arbor. “It’s really hard to lose both of them at the same time. My family will never be the same. And they were old, but I think we would have had a lot more years with them, if it wasn’t for covid.”

Grim said he isn’t certain how his grandparents contracted the virus. He remembers that the couple came into contact with someone who had the virus, but tested negative shortly thereafter. In August, Doris began experiencing heart attack-like symptoms.

“When they took her to the hospital, as protocol they did a covid test and found out that it was indeed the covid that was attacking her lungs and heart,” Grim said.

Jacob, who Grim called Pap-Pap, tested positive two days later, on Aug. 14. He was home for two weeks after Doris was hospitalized, but then his condition grew worse.

“All of a sudden, he just went downhill quickly” Grim said. “And we really think that because Grandma was such a caretaker, she wanted to make sure he passed before she was ready to go.”

Grim said that after Doris died, the family found a notebook where she kept count of how many newborn hats she had made for the hospital: 3,241 in all.

Before the pandemic, Doris enjoyed going out to play Bingo with her daughter Theresa on Wednesday nights and playing a Japanese card game called Hanafuda on Sundays, Grim said. She hated staying home during the pandemic, and even called it “jail.”

The couple tended to their garden, where they planted vegetables such as tomatoes, peppers, and squash. Grim said when Doris was in the hospital, the doctors told the family she was delirious and was talking about her cantaloupes being ready. But when Grim visited the garden afterward, he found “two perfectly bright cantaloupes.”

Doris would have turned 82 last week. The family didn’t come together to observe her birthday out of safety concerns. But Grim and his brother, Josh, bought anthuriums, a tropical flower their grandmother loved, to put on her grave.

Source Article

Read more

Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint

ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy  

Paltusotine was observed to be well tolerated among the 60 participants in the ACROBAT Edge and Evolve Studies

On Track to Initiate Phase 3 Paltusotine Program in 1H 2021

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) —  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced positive topline results from the company’s Phase 2 ACROBAT Edge and ACROBAT Evolve studies of paltusotine (formerly CRN00808), the company’s lead candidate for the treatment of acromegaly. The Company will hold a conference call at 8:00 a.m. Eastern Time today to discuss these results. In addition, a Key Opinion Leader (KOL) call will be held on November 20th to discuss these results in the context of the current standard of care with clinical experts.

The prespecified primary endpoint in Edge was achieved, showing that once daily oral paltusotine maintained insulin-like growth factor-1  (IGF-1) levels at Week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand  (SRL) depot of either octreotide or lanreotide monotherapy  [change in IGF-1 = -0.034  (-0.107, 0.107), median (IQR)]. There were 25 patients enrolled in this prespecified primary analysis population (Group 1). During the four-week washout period after the 13-week treatment period, Group 1 patients showed a meaningful  (>20%) and prompt  (within two weeks) rise in IGF-1 levels from baseline, which characterized the magnitude of therapeutic activity of oral paltusotine in acromegaly patients. Edge also enrolled an additional 22 patients into four different exploratory populations  (Groups 2-5). 

Paltusotine was generally well tolerated among the 60 ACROBAT participants (including both Edge and Evolve), which is consistent with prior clinical findings in healthy volunteers. There were no discontinuations due to drug-related adverse events, no safety signals seen in clinical laboratory analyses, no treatment-related serious adverse events (SAEs), and no patients required rescue treatments with standard acromegaly medications during treatment. The most common treatment-emergent adverse events (>10%) included: headache, arthralgia, fatigue, peripheral swelling, paresthesia and hyperhidrosis.

“These results from Edge and Evolve support the potential to effectively switch acromegaly patients from their current depot injections to a once-daily oral treatment while maintaining hormonal control,” stated Alan Krasner M.D., Chief Medical Officer of Crinetics. “The heterogeneous nature of the ACROBAT patient population is representative of the real-world population, where acromegaly patients are prescribed a variety of treatments in an effort to control their IGF-1 levels, often unsuccessfully. The potential for once daily oral paltusotine to offer similar disease control provided by first-line injected depot SRLs gives us confidence to move into a Phase 3 program to further evaluate the efficacy and safety of paltusotine.”

Scott Struthers, Ph.D., founder and Chief Executive Officer of Crinetics, added, “Overall, we believe these findings support our thesis that once daily oral paltusotine has the potential to replace injected peptide depots for acromegaly therapy. We

Read more